Last reviewed · How we verify
NCT02085395: AK
An Open Phase II Study to Assess the Efficacy and Safety of Topical SR-T100® Gel in the Treatment of Human Cutaneous Squamous Cell Carcinoma in Situ (Actinic Keratosis and Bowen's Disease)
Phase 2 trial testing SR-T100 ® Gel in Actinic Keratosis in 27 participants. Completed in 1 November 2010.
1 April 2010
Quick facts
| Lead sponsor | G&E Herbal Biotechnology Co., LTD |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 27 |
| Start date | 1 November 2007 |
| Primary completion | 1 April 2010 |
| Estimated completion | 1 November 2010 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- SR-T100 ® Gel
Conditions studied
- Actinic Keratosis — all drugs for Actinic Keratosis →
- Bowen's Disease — all drugs for Bowen's Disease →
Sponsor
G&E Herbal Biotechnology Co., LTD — full company profile →
Who can join
20 and older, any sex, with Actinic Keratosis or Bowen's Disease. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Partial clearance rate
Time frame: 16 weeks treatment and 4 weeks follow-up
To assess the response rate of SR-T100® gel in patients with cutaneous squamous cell carcinoma in situ (Actinic Keratosis: AK; and Bowen's Disease: BD), defined as the proportion of patients whose lesion size (length x width x height) reduced \> 75%.
Sponsor's own description
To evaluate the efficacy of SR-T100 gel by observing the lesion size (length x width x height) of human cutaneous squamous cell carcinoma in situ (Actinic Keratosis and Bowen's Disease) reduced at least 75%.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Antimicrobial and Anti-Infective Potential of Herbal Creams in Dermatology: Efficacy, Safety, and Challenges in Skin Infection Management.
Brar GS, Nandy SK, Sharma A, Siddiqui AJ, et al · · 2025 · PMID 41362433 · DOI 10.2147/idr.s565852
Verify or expand the search:
- PubMed search for NCT02085395
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Actinic Keratosis
Currently open trials in the same condition.
- NCT06778434 — The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans · Phase 2 · recruiting
- NCT05699603 — Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Prec · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02085395 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by G&E Herbal Biotechnology Co., LTD
- Last refreshed: 13 March 2014
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02085395.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing